Efficacy of Two-Weekly Nanoparticle Albumin-Bound Paclitaxel as Neoadjuvant Chemotherapy for Breast Cancer

Abstract

Aim: Compare the two-weekly regimens of nanoparticle albumin-bound paclitaxel (nab-P) with solvent-based paclitaxel (sb-P) as neoadjuvant chemotherapy for breast cancer. Materials & methods: Patients (n = 162) with operable early breast cancer received four cycles of dose-dense epirubicin and cyclophosphamide followed by four two-weekly cycles of nab-P (n = 83) or sb-P (n = 79), with trastuzumab when needed. Results: Across all the patients, the ypT0 ypN0 and ypT0/is ypN0 pathological complete response rates in the nab-P group were not superior to those in the sb-P group. However, pathological complete response rates for triple-negative breast cancer were significantly better with nab-P than with sb-P. Meanwhile, nab-P also induced more peripheral sensory neuropathy. Conclusion: The two-weekly nab-P regimen is a good neoadjuvant chemotherapy choice for triple-negative breast cancer.

Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis

“…Pooling the data of all five studies 8 , 9 , 16 – 18 that assessed pCR (ypT0/is ypN0) in 2335 patients, a significant difference favoring nab-paclitaxel was identified (OR = 1.39, 95% CI = 1.16–1.67; P < 0.001; Figure 2 ) with no heterogeneity found among the studies (χ 2 = 1.34, I 2 = 0%).…”

“…Pooling the data from three studies 9 , 17 , 18 that assessed pCR (ypT0 ypN0) among 364 patients with TNBC, a significant difference favoring nab-paclitaxel was observed (OR = 2.45, 95% CI = 1.57–3.82, P < 0.001) with moderate heterogeneity noted among the studies (χ 2 = 3.24, I 2 = 38%). Pooling the data of two studies 9 , 18 that assessed pCR (ypT0 ypN0) in 449 patients with HER2-positive breast cancer, comparable efficacy was noted between the two groups (OR = 1.31, 95% CI = 0.89–1.92) with low heterogeneity found among the studies (χ 2 = 1.05, I 2 = 5%).…”

“…Five studies 8 , 9 , 16 – 18 were identified using the predefined search strategy in the final analysis. Two 19 , 20 studies reported survival after short follow-up periods.…”

“…The study characteristics, patient demographics, regimens, dosages, and quality score for each study are shown in Table 1 . The analyzed studies included three RCTs, 8 , 9 , 17 one retrospective study, 18 and one matched case-control study. 16 The details of the quality assessment are shown in Tables 2 and 3 .…”

Exosomal non‑coding RNAs: Novel biomarkers with emerging clinical applications in gastric cancer (Review)

“…Combined use of novel drugs is a new technique in the treatment of advanced GC. Paclitaxel is considered to be the optimum natural anticancer drug found thus far, and has been widely used in the treatment of GC, breast cancer ( 104 ), ovarian cancer ( 105 ), partial head and neck cancer ( 106 ), and lung cancer ( 107 ). However, chemotherapy resistance of paclitaxel in patients with GC is an issue that needs to be addressed ( 108 , 109 ).…”